Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3809)
All Articles published online
|
Publishing Process of This Article
|
Oct 28, 2024 (publication date) through Mar 2, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Zhang H, Dong X, Zhu L, Tang FS. Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease. World J Gastroenterol 2024; 30(40): 4393-4398 [PMID: 39494094 DOI: 10.3748/wjg.v30.i40.4393] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Zhang H, Dong X, Zhu L, Tang FS. Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease. World J Gastroenterol 2024; 30(40): 4393-4398 [PMID: 39494094 DOI: 10.3748/wjg.v30.i40.4393] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v30/i40/4393.htm |
| Number | Citing Articles |
| 1 |
Ana Paula Madariaga Traconis, Misael Uribe-Esquivel, Varenka Julieta Barbero Becerra. Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease. Cells 2024; 13(24): 2055 doi: 10.3390/cells13242055
|
| 2 |
Samira Farhadi, Saeed Mohammadi, Abdulaziz Y AlKindi, Issa S Al-Amri. Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction. World Journal of Biological Chemistry 2025; 16(1): 104535 doi: 10.4331/wjbc.v16.i1.104535
|
| 3 |
Rong Hu, Dan Liu, Xiaofei Sun, Zhong Yu. New drugs approved by European medicines agency during 2024. European Journal of Medicinal Chemistry 2025; 294: 117761 doi: 10.1016/j.ejmech.2025.117761
|
| 4 |
Iuliana Popescu. PPARevolution. First PPARδ Agonist and a Dual PPARα/PPARδ Activator Approved for the Treatment of Primary Biliary Cholangitis. Journal of Cellular and Molecular Medicine 2025; 29(21) doi: 10.1111/jcmm.70948
|
| 5 |
Liver Cirrhosis - Current Challenges and Emerging Technologies [Working Title]. 2026; doi: 10.5772/intechopen.1012482
|
| 6 |
Shujiao He, Kexin Wang, Binghui Li, Wei Fang, Xinyi Wei, Fen Yao, Nan Wang, Xiaoxia Wang, Ying Zhang, Yi Gao, Yang Li, Shao Li, Shuqin Zhou, Juan Du, Qing Peng. Therapeutic potential of TMSC-Exo for non-alcoholic fatty liver disease using the liver-on-a-chip model. Journal of Translational Internal Medicine 2026; 14(1): 134 doi: 10.1515/jtim-2026-0007
|
| 7 |
Mengyao Duan, Ying Wu, Jie Zhang, Saman Azeem, Yao Dong, Zhonghui Gai, Jianguo Zhu, Shuguang Fang, Shaobin Gu. Weizmannia coagulans BC179 Alleviates Post-Alcohol Discomfort May via Taurine-Related Metabolism and Antioxidant Regulation: A Randomized, Double-Blind, Placebo-Controlled Trial. Antioxidants 2025; 14(9): 1038 doi: 10.3390/antiox14091038
|
| 8 |
Chen-Ying Zhu, Pei-Han Yu, Qi Sun, De-Fei Hong, Chang Yang, Hua Naranmandura. Nuclear receptors in metabolism and diseases: Mechanistic and therapeutic insights. Pharmacological Research 2025; 218: 107862 doi: 10.1016/j.phrs.2025.107862
|